CYP1A2 Gene (Protein Coding)

Cytochrome P450 Family 1 Subfamily A Member 2

GC15P074748
GIFtS:
46
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The protein encoded by this gene localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons ... See more...

Aliases for CYP1A2 Gene

Aliases for CYP1A2 Gene

  • Cytochrome P450 Family 1 Subfamily A Member 2 2 3 5
  • Cytochrome P450, Subfamily I (Aromatic Compound-Inducible), Polypeptide 2 2 3
  • Cytochrome P450, Family 1, Subfamily A, Polypeptide 2 2 3
  • Hydroperoxy Icosatetraenoate Dehydratase 3 4
  • Cholesterol 25-Hydroxylase 3 4
  • Cytochrome P450 1A2 3 4
  • Cytochrome P(3)450 3 4
  • Cytochrome P450-P3 3 4
  • Cytochrome P450 4 3 4
  • EC 1.14.14.1 4 50
  • CYPIA2 3 4
  • P3-450 2 3
  • CP12 2 3
  • Flavoprotein-Linked Monooxygenase 3
  • Aryl Hydrocarbon Hydroxylase 3
  • Microsomal Monooxygenase 3
  • Xenobiotic Monooxygenase 3
  • Dioxin-Inducible P3-450 3
  • EC 4.2.1.152 4
  • P450 Form 4 3
  • P450(PA) 3
  • CYP1A2 5

External Ids for CYP1A2 Gene

Previous GeneCards Identifiers for CYP1A2 Gene

  • GC15M070968
  • GC15M068160
  • GC15P072617
  • GC15P072757
  • GC15P072828
  • GC15P075041
  • GC15P051838

Summaries for CYP1A2 Gene

Entrez Gene Summary for CYP1A2 Gene

  • This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The protein encoded by this gene localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of which are found in cigarette smoke. The enzyme's endogenous substrate is unknown; however, it is able to metabolize some PAHs to carcinogenic intermediates. Other xenobiotic substrates for this enzyme include caffeine, aflatoxin B1, and acetaminophen. The transcript from this gene contains four Alu sequences flanked by direct repeats in the 3' untranslated region. [provided by RefSeq, Jul 2008]

GeneCards Summary for CYP1A2 Gene

CYP1A2 (Cytochrome P450 Family 1 Subfamily A Member 2) is a Protein Coding gene. Diseases associated with CYP1A2 include Porphyria Cutanea Tarda and Acetaminophen Metabolism. Among its related pathways are Naphthalene metabolism and Arachidonic acid metabolism. Gene Ontology (GO) annotations related to this gene include enzyme binding and iron ion binding. An important paralog of this gene is CYP1A1.

UniProtKB/Swiss-Prot Summary for CYP1A2 Gene

  • A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:9435160, PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:9435160, PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:11555828, PubMed:12865317). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2 (PubMed:11555828, PubMed:12865317). Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376). Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer (PubMed:19965576). Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA (PubMed:9435160). May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent) (PubMed:21068195). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin (PubMed:14725854). Metabolizes caffeine via N3-demethylation (Probable).

Gene Wiki entry for CYP1A2 Gene

PharmGKB "VIP" Summary for CYP1A2 Gene

Additional gene information for CYP1A2 Gene

No data available for CIViC Summary , Tocris Summary , Rfam classification and piRNA Summary for CYP1A2 Gene

Genomics for CYP1A2 Gene

GeneHancer (GH) Regulatory Elements Pubs

Download GeneHancer 2017 data
Promoters and enhancers for CYP1A2 Gene
GeneHancer (GH) Identifier GH Type GH
Score		 GH Sources Gene Association Score Total Score TSS distance (kb) Number of Genes Away Size (kb) Transcription Factor
Binding Sites		 Gene Targets
GH15J074748 Promoter 0.6 EPDnew 250.7 0.0 -19 0.1 YY1 RXRA HNF4A SP1 SREBF1 CYP1A2 piR-54764-215 CYP1A1
GH15J074750 Enhancer 0.2 Ensembl 250.7 +1.7 1656 0.2 CYP1A2 lnc-CYP1A1-3 CSK
GH15J074725 Promoter/Enhancer 1.8 EPDnew FANTOM5 Ensembl ENCODE 0.4 -22.6 -22644 2 CEBPA ZNF10 ZIC2 ZBTB10 CHD2 ZNF341 KLF7 NR2C1 MAX ZNF217 CYP1A1 RPP25 ENSG00000260103 ARID3B C15orf39 SCAMP2 piR-36393-182 CYP1A2
GH15J074730 Enhancer 1 Ensembl ENCODE 0.4 -17.8 -17781 1.7 CEBPA YY1 HOMEZ THAP11 FOXA2 KDM6A MAFF SMAD4 RXRA SAP130 piR-31162-157 piR-45471-209 piR-61028-189 piR-54764-215 EDC3 FAM219B CYP1A1 CYP1A2
GH15J074770 Enhancer 1.1 ENCODE dbSUPER 0.4 +22.6 22555 0.8 BCLAF1 MYC ZNF654 ZNF600 ZBTB10 CTCF REST ZNF592 DEK TRIM22 ULK3 CPLX3 SCAMP5 PPCDC HSALNG0107216 CSK lnc-CYP1A1-3 CYP1A2
- Elite GeneHancer and/or Elite GeneHancer-gene association Download GeneHancer data from 2017 publication | Request up-to-date GeneHancer data (full dataset)

GeneHancers around CYP1A2 on the GeneHancer Hub at the UCSC Golden Path

Cistromic (ChIP-Seq) regulation report from SPP (The Signaling Pathways Project) for CYP1A2

Top Transcription factor binding sites by QIAGEN in the CYP1A2 gene promoter:
  • Arnt
  • C/EBPalpha
  • GR
  • GR-alpha
  • HNF-4alpha1
  • Ik-2
  • MZF-1
  • Nkx5-1
  • p53
  • Pax-2

Genomic Locations for CYP1A2 Gene

Latest Assembly
chr15:74,748,845-74,756,607
(GRCh38/hg38)
Size:
7,763 bases
Orientation:
Plus strand

Previous Assembly
chr15:75,041,186-75,048,948
(GRCh37/hg19 by Entrez Gene)
Size:
7,763 bases
Orientation:
Plus strand

chr15:75,041,185-75,048,543
(GRCh37/hg19 by Ensembl)
Size:
7,359 bases
Orientation:
Plus strand

Genomic View for CYP1A2 Gene

Genes around CYP1A2 on UCSC Golden Path with GeneCards custom track

Cytogenetic band:
CYP1A2 Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
Genomic Location for CYP1A2 Gene
GeneLoc Logo Genomic Neighborhood • Exon Structure • Gene Density

RefSeq DNA sequence for CYP1A2 Gene

Proteins for CYP1A2 Gene

Products:

  1. Antibodies for research
  2. Protein products for research
  3. Assay products for research

  • Protein details for CYP1A2 Gene (UniProtKB/Swiss-Prot)

    Protein Symbol:
    P05177-CP1A2_HUMAN
    Recommended name:
    Cytochrome P450 1A2
    Protein Accession:
    P05177
    Secondary Accessions:
    • Q16754
    • Q6NWU3
    • Q6NWU5
    • Q9BXX7
    • Q9UK49

    Protein attributes for CYP1A2 Gene

    Size:
    516 amino acids
    Molecular mass:
    58407 Da
    Cofactor:
    Name=heme; Xref=ChEBI:CHEBI:30413;
    Quaternary structure:
    • Interacts with PGRMC1; the interaction requires PGRMC1 homodimerization.

    Three dimensional structures from OCA and Proteopedia for CYP1A2 Gene

neXtProt entry for CYP1A2 Gene

Protein Expression for CYP1A2 Gene

See protein expression from ProteomicsDB, MOPED, PaxDb, and MaxQB

Selected DME Specific Peptides for CYP1A2 Gene

P05177:
  • LLQQLEFS
  • LEAFILE
  • TTAISWSL
  • QGDDFKGRP
  • CVFVNQWQ
  • YLPNPAL
  • ELDTVIG
  • RRPRLSDR
  • PHSTTRDT
  • YGDVLQI
  • WAARRRLAQ
  • FGAGFDT
  • FSIASDP
  • PILRYLP
  • LQRFKAFNQ
  • PEIQRKIQ
  • GKRRCIGE
  • SATELLL
  • PFTIPHST
  • VIGAMCFG
  • LTLGKNPH
  • TPIYGLT
  • FRPERFLT
  • LNGFYIP
  • DRPQLPY

Post-translational modifications for CYP1A2 Gene

  • Glycosylation at Ser69
  • Modification sites at PhosphoSitePlus

Other Protein References for CYP1A2 Gene

ENSEMBL proteins:
REFSEQ proteins:

Domains & Families for CYP1A2 Gene

Gene Families for CYP1A2 Gene

HGNC:
IUPHAR :
Human Protein Atlas (HPA):
  • Cancer-related genes
  • Enzymes
  • Predicted membrane proteins

Protein Domains for CYP1A2 Gene

InterPro:
Blocks:
  • E-class P450 group I signature
  • CYP1A P450 family signature

Suggested Antigen Peptide Sequences for CYP1A2 Gene

GenScript: Design optimal peptide antigens:
  • Cytochrome P450-P3 (CP1A2_HUMAN)
  • Cytochrome P450, family 1, subfamily A, polypeptide 2 (Q6NWU3_HUMAN)

Graphical View of Domain Structure for InterPro Entry

P05177

UniProtKB/Swiss-Prot:

CP1A2_HUMAN :
  • Belongs to the cytochrome P450 family.
Family:
  • Belongs to the cytochrome P450 family.
genes like me logo Genes that share domains with CYP1A2: view

Function for CYP1A2 Gene

Products:

  1. Animal Models for research
  2. CRISPR products for research
  3. miRNA products for research
  4. Inhibitory RNAs for research
  5. Clone products for research
  6. Cell Lines for research

Molecular function for CYP1A2 Gene

UniProtKB/Swiss-Prot Function:
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:9435160, PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:9435160, PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:11555828, PubMed:12865317). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2 (PubMed:11555828, PubMed:12865317). Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376). Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer (PubMed:19965576). Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA (PubMed:9435160). May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent) (PubMed:21068195). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin (PubMed:14725854). Metabolizes caffeine via N3-demethylation (Probable).
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=an organic molecule + O2 + reduced [NADPH--hemoprotein reductase] = an alcohol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:17149, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30879, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:142491; EC=1.14.14.1; Evidence={ECO:0000269|PubMed:11555828, ECO:0000269|PubMed:12865317, ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-estradiol + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxy-17beta-estradiol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47212, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16469, ChEBI:CHEBI:28744, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:11555828, ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-estradiol + O2 + reduced [NADPH--hemoprotein reductase] = 4-hydroxy-17beta-estradiol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47280, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16469, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:62845; Evidence={ECO:0000269|PubMed:11555828, ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=estrone + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxyestrone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47208, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:1156, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17263, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=estrone + O2 + reduced [NADPH--hemoprotein reductase] = 4-hydroxyestrone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47292, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17263, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:87602; Evidence={ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 25-hydroxycholesterol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50256, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16113, ChEBI:CHEBI:42977, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:21576599};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=all-trans-retinol + O2 + reduced [NADPH--hemoprotein reductase] = all-trans-retinal + H(+) + 2 H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:42092, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17336, ChEBI:CHEBI:17898, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:10681376};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=all-trans-retinal + O2 + reduced [NADPH--hemoprotein reductase] = all-trans-retinoate + 2 H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:42088, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17898, ChEBI:CHEBI:35291, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:10681376};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (14R,15S)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49860, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131965; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (14S,15R)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49856, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131964; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = (17R,18S)-epoxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39779, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:76634; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 + reduced [NADPH--hemoprotein reductase] = (19R,20S)-epoxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52120, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77016, ChEBI:CHEBI:136410; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5S)-hydroperoxy-(6E,8Z,11Z,14Z)-eicosatetraenoate = 5-oxo-(6E,8Z,11Z,14Z)-eicosatetraenoate + H2O; Xref=Rhea:RHEA:48632, ChEBI:CHEBI:15377, ChEBI:CHEBI:57450, ChEBI:CHEBI:65342; Evidence={ECO:0000269|PubMed:21068195};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoate = 12-oxo-(5Z,8Z,10E,14Z)-eicosatetraenoate + H2O; Xref=Rhea:RHEA:37947, ChEBI:CHEBI:15377, ChEBI:CHEBI:57444, ChEBI:CHEBI:75231; EC=4.2.1.152; Evidence={ECO:0000269|PubMed:21068195};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate = 15-oxo-(5Z,8Z,11Z,13E)-eicosatetraenoate + H2O; Xref=Rhea:RHEA:48636, ChEBI:CHEBI:15377, ChEBI:CHEBI:57410, ChEBI:CHEBI:57446; Evidence={ECO:0000269|PubMed:21068195};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(13S)-hydroperoxy-(9Z,11E)-octadecadienoate = 13-oxo-(9Z,11E)-octadecadienoate + H2O; Xref=Rhea:RHEA:48716, ChEBI:CHEBI:15377, ChEBI:CHEBI:57466, ChEBI:CHEBI:90781; Evidence={ECO:0000269|PubMed:21068195};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 13-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52292, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136524; Evidence={ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 19-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39759, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76627; Evidence={ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(9Z,12Z)-octadecadienoate + O2 + reduced [NADPH--hemoprotein reductase] = 11-hydroxy-(9Z,12Z)-octadecadienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52284, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30245, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136522; Evidence={ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot Induction:
By nicotine, omeprazole, phenobarbital, primidone and rifampicin.
UniProtKB/Swiss-Prot BiophysicochemicalProperties:
Kinetic parameters: KM=19 uM for 17beta-estradiol (2-hydroxylation) {ECO:0000269|PubMed:11555828}; KM=9 uM for all-trans retinol {ECO:0000269|PubMed:10681376}; KM=4 uM for 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole {ECO:0000269|PubMed:14725854}; KM=21 uM for 2-amino-3-methylimidazo[4,5-f]quinoline {ECO:0000269|PubMed:14725854}; KM=26 uM for 2-amino-2,4-dimethylimidazo[4,5-f]quinoline {ECO:0000269|PubMed:14725854}; KM=27 uM for 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline {ECO:0000269|PubMed:14725854}; KM=71 uM for 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine {ECO:0000269|PubMed:14725854}; KM=25 uM for phenacetin {ECO:0000269|PubMed:14725854}; Vmax=9.2 nmol/min/nmol enzyme toward 17beta-estradiol (2-hydroxylation) {ECO:0000269|PubMed:11555828}; Vmax=491 pmol/min/nmol enzyme toward all-trans retinol {ECO:0000269|PubMed:10681376};
GENATLAS Biochemistry:
cytochrome p450,family I (aromatic compound-inducible),member A2 (see CYP1@)

Enzyme Numbers (IUBMB) for CYP1A2 Gene

Phenotypes From GWAS Catalog for CYP1A2 Gene

Gene Ontology (GO) - Molecular Function for CYP1A2 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0004497 monooxygenase activity IDA,TAS --
GO:0005506 iron ion binding IEA --
GO:0005515 protein binding IPI 26988023
GO:0009055 electron transfer activity TAS 2813353
GO:0016491 oxidoreductase activity IDA 16401082
genes like me logo Genes that share ontologies with CYP1A2: view
genes like me logo Genes that share phenotypes with CYP1A2: view

Animal Models for CYP1A2 Gene

MGI Knock Outs for CYP1A2:

Animal Models for research

Inhibitory RNAs for research

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP1A2

No data available for Human Phenotype Ontology , Transcription Factor Targets and HOMER Transcription for CYP1A2 Gene

Localization for CYP1A2 Gene

Subcellular locations from UniProtKB/Swiss-Prot for CYP1A2 Gene

Endoplasmic reticulum membrane. Peripheral membrane protein. Microsome membrane. Peripheral membrane protein.

Subcellular locations from

COMPARTMENTS
Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
COMPARTMENTS Subcellular localization image for CYP1A2 gene
Compartment Confidence
extracellular 3
nucleus 3
endoplasmic reticulum 3
plasma membrane 2
cytoskeleton 2
mitochondrion 2
peroxisome 2
cytosol 2
golgi apparatus 2
endosome 1
lysosome 1

Gene Ontology (GO) - Cellular Components for CYP1A2 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0005783 endoplasmic reticulum IEA --
GO:0005789 endoplasmic reticulum membrane TAS --
GO:0016020 membrane IEA --
GO:0031090 organelle membrane IEA --
GO:0043231 intracellular membrane-bounded organelle IBA,IDA 2813353
genes like me logo Genes that share ontologies with CYP1A2: view

No data available for Subcellular locations from the Human Protein Atlas (HPA) for CYP1A2 Gene

Pathways & Interactions for CYP1A2 Gene

PathCards logo

SuperPathways for CYP1A2 Gene

SuperPathway Contained pathways
1 Cytochrome P450 - arranged by substrate type
Cytochrome P450 - arranged by substrate type
.64
Oxidation by Cytochrome P450
.64
Phase 1 - Functionalization of compounds
.63
Biological oxidations
.49
Phase II conjugation
.48
Xenobiotics
.39
Metapathway biotransformation
.36
Cannabidiol Pathway, Pharmacokinetics
.01
Doxepin Pathway, Pharmacokinetics
.01
Lidocaine Pathway, Pharmacokinetics
.01
Methylation
.01
Estradiol metabolism
.01
Fatty Acid Omega Oxidation
.01
2 Drug metabolism - cytochrome P450
Drug metabolism - cytochrome P450
.70
Metabolism of xenobiotics by cytochrome P450
.70
Chemical carcinogenesis
.68
Retinol metabolism
.33
Retinol metabolism
.31
Benzodiazepine Pathway, Pharmacokinetics
.01
Fluvoxamine Pathway, Pharmacokinetics
.01
Naproxen Pathway, Pharmacokinetics
.01
Benzo[a]pyrene metabolism
.01
Aflatoxin B1 metabolism
.01
Arylamine metabolism
.01
3 Imipramine/Desipramine Pathway, Pharmacokinetics
Imipramine/Desipramine Pathway, Pharmacokinetics
.57
Paroxetine Pathway, Pharmacokinetics
.57
Verapamil Pathway, Pharmacokinetics
.56
Amitriptyline and Nortriptyline Pathway, Pharmacokinetics
.50
Olanzapine Pathway, Pharmacokinetics
.50
Warfarin Pathway, Pharmacokinetics
.40
Clozapine Pathway, Pharmacokinetics
.38
Clomipramine Pathway, Pharmacokinetics
.01
Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2
.01
Lidocaine metabolism
.01
4 Caffeine Pathway, Pharmacokinetics
Caffeine metabolism
.50
Caffeine Pathway, Pharmacokinetics
.50
Theophylline Pathway, Pharmacokinetics
.01
Caffeine and Theobromine metabolism
.01
5 Acetaminophen Pathway (therapeutic doses), Pharmacokinetics
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics
.42
Acetaminophen metabolism
.42
2-Naphthylamine and 2-Nitronaphtalene metabolism
.31
Acetaminophen Pathway (toxic doses), Pharmacokinetics
.01
genes like me logo Genes that share pathways with CYP1A2: view

Pathways by source for CYP1A2 Gene

8 GeneGo (Thomson Reuters) pathways for CYP1A2 Gene
  • 2-Naphthylamine and 2-Nitronaphtalene metabolism
  • Acetaminophen metabolism
  • Androstenedione and testosterone biosynthesis and metabolism p.1
  • Benzo[a]pyrene metabolism
  • Estradiol metabolism
1 Cell Signaling Technology pathway for CYP1A2 Gene

UniProtKB/Swiss-Prot P05177-CP1A2_HUMAN

  • Pathway: Cofactor metabolism; retinol metabolism.
  • Pathway: Steroid metabolism; cholesterol metabolism.
  • Pathway: Lipid metabolism; arachidonate metabolism.

Gene Ontology (GO) - Biological Process for CYP1A2 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0006629 lipid metabolic process IEA --
GO:0006631 fatty acid metabolic process IEA --
GO:0006706 steroid catabolic process IMP 18356043
GO:0006725 cellular aromatic compound metabolic process IEA --
GO:0006778 porphyrin-containing compound metabolic process IEA --
genes like me logo Genes that share ontologies with CYP1A2: view

No data available for SIGNOR curated interactions for CYP1A2 Gene

Drugs & Compounds for CYP1A2 Gene

Products:

  1. Drug products for research

(514) Drugs for CYP1A2 Gene - From: DrugBank, PharmGKB, ClinicalTrials, ApexBio, HMDB, and Novoseek

Name Status Disease Links Group Role Mechanism of Action Clinical Trials
Caffeine Approved Pharma Enzyme, substrate, inhibitor 658
Carbamazepine Approved, Investigational Pharma Enzyme, inhibitor, inducer Inhibitor of neuronal voltage-gated Na+ channels; anticonvulsant 109
Fluvoxamine Approved, Investigational Pharma Enzyme, substrate, inhibitor 70
Ketoconazole Approved, Investigational Pharma Enzyme, inhibitor Inhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase, Cytochrome P450c17 inhibitor 196
Omeprazole Approved, Investigational, Vet_approved Pharma Enzyme, inducer H+,K+-ATPase inhibitor 457

(102) Additional Compounds for CYP1A2 Gene - From: Novoseek and HMDB

Name Synonyms Role CAS Number PubChem IDs PubMed IDs
1,7-Dimethyluric acid
  • 1,7-Dimethylate
  • 1,7-Dimethylic acid
  • 1,7-Dimethylurate
  • 7,9-Dihydro-1,7-dimethyl-1H-purine-2,6,8(3H)-trione
  • 1,7-Dimethyluric acid
 33868-03-0
1-Methylxanthine
6136-37-4
Aflatoxin B1
  • 2,3,6Aalpha,9aalpha-tetrahydro-4-methoxycyclopenta(c)furo(3',2':4,5)furo(2,3-H)(1)benzopyran-1,11-dione
  • Aflatoxin b1 dihydrochloride, (6ar-cis)-isomer
  • Aflatoxin b1, (6ar-cis)-isomer, 14C-labeled
  • Aflatoxin b1, (6ar-cis)-isomer, 2H-labeled
  • Aflatoxin b1, cis(+,-)-isomer
 1162-65-8
Paraxanthine
  • 3,7-Dihydro-1,7-dimethyl-1H-purine-2,6-dione
  • p-Xanthine
  • 1,7-Dimethyl-xanthine
  • 1,7-Dimethylxanthine
 611-59-6
11,12,15-THETA
  • 11,12,15-Trihydroxyicosatrienoic acid
  • (5Z,8Z,13E)-(15S)-11,12,15-Trihydroxyeicosa-5,8,12-trienoic acid
  • (5Z,8Z,13E)-(15S)-11,12,15-Trihydroxyicosa-5,8,12-trienoic acid
  • 11,12,15-Trihydroxyicosatrienoate
  • (5Z,8Z,13E)-(15S)-11,12,15-Trihydroxyeicosa-5,8,12-trienoate

(7) ApexBio Compounds for CYP1A2 Gene

Compound Action Cas Number
Abiraterone acetate Cytochrome p450 17a1 inhibitor 154229-18-2
Avasimibe ACAT inhibitor,orally bioavailable 166518-60-1
Gemfibrozil 25812-30-0
Ifosfamide Cytostatic agent 3778-73-2
Ketoconazole Inhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase 65277-42-1
Methoxyresorufin 5725-89-3
Oltipraz An antischistosomal agent 64224-21-1
genes like me logo Genes that share compounds with CYP1A2: view

Drug products for research

Transcripts for CYP1A2 Gene

Products:

  1. CRISPR products for research
  2. miRNA products for research
  3. Inhibitory RNAs for research
  4. Clone products for research

mRNA/cDNA for CYP1A2 Gene

1 REFSEQ mRNAs :
10 NCBI additional mRNA sequence :
1 Ensembl transcripts including schematic representations, and UCSC links to gene/alias where relevant :

Inhibitory RNAs for research

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP1A2

Alternative Splicing Database (ASD) splice patterns (SP) for CYP1A2 Gene

No ASD Table

Relevant External Links for CYP1A2 Gene

GeneLoc Exon Structure for
CYP1A2

Expression for CYP1A2 Gene

Products:

  1. Primer products for research
  2. Gene Expression Assays for research

mRNA expression in normal human tissues from GTEx, Illumina, BioGPS, and SAGE for CYP1A2 Gene

mRNA expression in normal human tissues for CYP1A2 Gene
mRNA expression by BioGPS for CYP1A2 GenemRNA expression by GTEx for CYP1A2 Gene

mRNA expression in embryonic tissues and stem cells from LifeMap Discovery

mRNA differential expression in normal tissues according to GTEx for CYP1A2 Gene

This gene is overexpressed in Liver (x51.8).

Protein differential expression in normal tissues from HIPED for CYP1A2 Gene

This gene is overexpressed in Gallbladder (51.2) and Liver (17.4).

Integrated Proteomics: protein expression in normal tissues and cell lines from ProteomicsDB, MaxQB, and MOPED for CYP1A2 Gene



Protein tissue co-expression partners for CYP1A2 Gene

- Elite partner

Transcriptomic regulation report from SPP (The Signaling Pathways Project) for CYP1A2

SOURCE GeneReport for Unigene cluster for CYP1A2 Gene:

Hs.1361

mRNA Expression by UniProt/SwissProt for CYP1A2 Gene:

P05177-CP1A2_HUMAN
Tissue specificity: Liver.

Evidence on tissue expression from TISSUES for CYP1A2 Gene

  • Liver(4.8)
  • Blood(2.6)
  • Urine(2.6)
  • Intestine(2.6)
  • Heart(2.3)
  • Kidney(2.2)
  • Nervous system(2.1)
  • Skin(2.1)
genes like me logo Genes that share expression patterns with CYP1A2: view

Primer products for research

No data available for Phenotype-based relationships between genes and organs from Gene ORGANizer for CYP1A2 Gene

Orthologs for CYP1A2 Gene

This gene was present in the common ancestor of eukaryotes.

Orthologs for CYP1A2 Gene

Organism Taxonomy Gene Similarity Type Details
Chimpanzee
(Pan troglodytes)
 Mammalia CYP1A2 30
  • 98 (a)
 OneToOne
LOC735881 29
  • 92.81 (n)
Cow
(Bos Taurus)
 Mammalia CYP1A2 29 30
  • 85.14 (n)
 OneToOne
Dog
(Canis familiaris)
 Mammalia CYP1A2 29 30
  • 84.31 (n)
 OneToOne
Rat
(Rattus norvegicus)
 Mammalia Cyp1a2 29
  • 80.6 (n)
Mouse
(Mus musculus)
 Mammalia Cyp1a2 29 16 30
  • 80.01 (n)
 OneToOne
Oppossum
(Monodelphis domestica)
 Mammalia -- 30
  • 65 (a)
 ManyToMany
-- 30
  • 65 (a)
 ManyToMany
Platypus
(Ornithorhynchus anatinus)
 Mammalia -- 30
  • 65 (a)
 OneToMany
Chicken
(Gallus gallus)
 Aves CYP1A1 30
  • 60 (a)
 ManyToMany
CYP1A4 30
  • 55 (a)
 ManyToMany
Lizard
(Anolis carolinensis)
 Reptilia -- 30
  • 59 (a)
 ManyToMany
-- 30
  • 56 (a)
 ManyToMany
-- 30
  • 54 (a)
 ManyToMany
Zebrafish
(Danio rerio)
 Actinopterygii cyp1a 30
  • 53 (a)
 OneToMany
Rainbow Trout
(Oncorhynchus mykiss)
 Actinopterygii Omy.11738 29
Fruit Fly
(Drosophila melanogaster)
 Insecta Cyp307a1 31
  • 26 (a)
spok 30
  • 23 (a)
 ManyToMany
spo 30
  • 22 (a)
 ManyToMany
Thale Cress
(Arabidopsis thaliana)
 eudicotyledons CYP703A2 29
  • 41.45 (n)
Rice
(Oryza sativa)
 Liliopsida Os08g0131100 29
  • 44.3 (n)
Sea Squirt
(Ciona savignyi)
 Ascidiacea -- 30
  • 30 (a)
 ManyToMany
-- 30
  • 19 (a)
 ManyToMany
Species where no ortholog for CYP1A2 was found in the sources mined by GeneCards:
  • A. gosspyii yeast (Eremothecium gossypii)
  • Actinobacteria (Mycobacterium tuberculosis)
  • African clawed frog (Xenopus laevis)
  • African malaria mosquito (Anopheles gambiae)
  • Alicante grape (Vitis vinifera)
  • Alpha proteobacteria (Wolbachia pipientis)
  • Amoeba (Dictyostelium discoideum)
  • Archea (Pyrococcus horikoshii)
  • Baker's yeast (Saccharomyces cerevisiae)
  • Barley (Hordeum vulgare)
  • Beta proteobacteria (Neisseria meningitidis)
  • Bread mold (Neurospora crassa)
  • Chromalveolata (Phytophthora infestans)
  • Common water flea (Daphnia pulex)
  • Corn (Zea mays)
  • E. coli (Escherichia coli)
  • Filamentous fungi (Aspergillus nidulans)
  • Firmicute Bacteria (Streptococcus pneumoniae)
  • Fission Yeast (Schizosaccharomyces pombe)
  • Green Algae (Chlamydomonas reinhardtii)
  • Honey Bee (Apis mellifera)
  • K. Lactis Yeast (Kluyveromyces lactis)
  • Loblloly Pine (Pinus taeda)
  • Malaria Parasite (Plasmodium falciparum)
  • Medicago Trunc (Medicago Truncatula)
  • Moss (Physcomitrella patens)
  • Orangutan (Pongo pygmaeus)
  • Pig (Sus scrofa)
  • Rice Blast Fungus (Magnaporthe grisea)
  • Schistosome Parasite (Schistosoma mansoni)
  • Sea Anemone (Nematostella vectensis)
  • Sea Vase (Ciona intestinalis)
  • Sea Urchin (Strongylocentrotus purpuratus)
  • Sorghum (Sorghum bicolor)
  • Soybean (Glycine max)
  • Stem Rust Fungus (Puccinia graminis)
  • Sugarcane (Saccharum officinarum)
  • Tomato (Lycopersicon esculentum)
  • Toxoplasmosis (Toxoplasma gondii)
  • Trichoplax (Trichoplax adhaerens)
  • Tropical Clawed Frog (Silurana tropicalis)
  • Wheat (Triticum aestivum)
  • Worm (Caenorhabditis elegans)

Evolution for CYP1A2 Gene

ENSEMBL:
Gene Tree for CYP1A2 (if available)
TreeFam:
Gene Tree for CYP1A2 (if available)
Aminode:
Evolutionary constrained regions (ECRs) for CYP1A2: view image
Alliance of Genome Resources:
Additional Orthologs for CYP1A2

Paralogs for CYP1A2 Gene

Paralogs for CYP1A2 Gene

(25) SIMAP similar genes for CYP1A2 Gene using alignment to 2 proteins:

  • CP1A2_HUMAN
  • Q6NWU3_HUMAN
genes like me logo Genes that share paralogs with CYP1A2: view

Variants for CYP1A2 Gene

Products:

  1. SNP Genotyping and Copy Number Assays for research

Polymorphic Variants from UniProtKB/Swiss-Prot for CYP1A2 Gene

CP1A2_HUMAN-P05177
The CYP1A2*1F allele which is quite common (40 to 50%) is due to a substitution of a base in the non-coding region of the CYP1A2 gene and has the effect of decreasing the enzyme inducibility. Individuals who are homozygous for the CYP1A2*1F allele are 'slow' caffeine metabolizers. Thus for these individual increased intake of caffeine seems to be associated with a concomitant increase in the risk of non-fatal myocardial infraction (MI).

Sequence variations, with clinical significance, from ClinVar and Humsavar, with links to dbSNP for CYP1A2 Gene

SNP ID Clinical significance and condition Chr 15 pos Variation AA Info Type
675798 Benign: not provided 74,755,085(+) T/.
NM_000761.5(CYP1A2):c.1548= (p.Asn516=) 		NO_SEQUENCE_ALTERATION
rs17861154 Likely Benign: not provided 74,750,044(+) C/T
NM_000761.5(CYP1A2):c.306C>T (p.Gly102=) 		SYNONYMOUS
rs2470890 Benign: not provided 74,755,085(+) T/C
NM_000761.5(CYP1A2):c.1548T>C (p.Asn516=) 		SYNONYMOUS
rs34153904 Likely Benign: not provided 74,750,131(+) G/A
NM_000761.5(CYP1A2):c.393G>A (p.Pro131=) 		SYNONYMOUS
rs45468096 Likely Benign: not provided 74,751,198(+) C/Tp.Arg281Trp
NM_000761.5(CYP1A2):c.841C>T (p.Arg281Trp) 		MISSENSE

dbSNP identifiers (rs#s) for variants without ClinVar clinical significance for CYP1A2 Gene

All consequence types are included: molecular consequences (e.g. missense, synonymous), and location-based (e.g. intron, upstream).

Structural Variations from Database of Genomic Variants (DGV) for CYP1A2 Gene

Variant ID Type Subtype PubMed ID
esv3581763 CNV loss 25503493
nsv1121512 CNV deletion 24896259
nsv833055 CNV loss 17160897

Variation tolerance for CYP1A2 Gene

Residual Variation Intolerance Score: 79.2% of all genes are more intolerant (likely to be disease-causing)
Gene Damage Index Score: 2.60; 44.99% of all genes are more intolerant (likely to be disease-causing)

Additional Variant Information for CYP1A2 Gene

The Human Cytochrome P450 Allele Nomenclature Database
CYP1A2
Human Gene Mutation Database (HGMD)
CYP1A2
SNPedia medical, phenotypic, and genealogical associations of SNPs for
CYP1A2
Leiden Open Variation Database (LOVD)
CYP1A2

SNP Genotyping and Copy Number Assays for research

Disorders for CYP1A2 Gene

MalaCards: The human disease database

(38) MalaCards diseases for CYP1A2 Gene - From: COP and GCD

Disorder Aliases PubMed IDs
porphyria cutanea tarda
  • pct
acetaminophen metabolism
antley-bixler syndrome
  • trapezoidocephaly-synostosis syndrome
hepatocellular adenoma
  • adenoma hepatocellular
female stress incontinence
  • female urinary stress incontinence
- elite association - COSMIC cancer census association via MalaCards

Additional Disease Information for CYP1A2

Human Genome Epidemiology Navigator
(HuGE)
Atlas
ATLAS of Genetics and Cytogenetics in Oncology and Haematology
Open Targets Platform
Open Targets Platform
genes like me logo Genes that share disorders with CYP1A2: view

No data available for UniProtKB/Swiss-Prot and Genatlas for CYP1A2 Gene

Publications for CYP1A2 Gene

  1. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. (PMID: 19424794) MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (Breast cancer research and treatment 2010) 3 22 40
  2. Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. (PMID: 19776291) Ferlin A … Foresta C (Endocrine-related cancer 2010) 3 22 40
  3. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. (PMID: 18690546) Altayli E … Bek Y (International urology and nephrology 2009) 3 22 40
  4. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. (PMID: 19450128) Gunes A … Dahl ML (Pharmacogenomics 2009) 3 22 40
  5. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. (PMID: 19415745) Sangrajrang S … Yoshida T (International journal of cancer 2009) 3 22 40

ExternalLinks

View latest publications for CYP1A2 gene in Mastermind

Products for CYP1A2 Gene

Sources for CYP1A2 Gene